The AHA Guidelines and Scientific Statements Handbook

Index

Microvolt T Wave Alternans Testing for Risk Stratifi cation
of Post MI Patients 291
Mitral regurgitation. See MR
Mitral valve prolapse 304–5
MLP 238, 240
Moexipril 227
Monotherapy 319
Morphine 34, 54
Mortality 140–3, 146, 278, 281, 292
arrhythmic 280
nonarrhythmic 280
rate, annual 11
Moxonidine 204, 210
MR 144, 281, 302–9, 311
chronic 306
residual 306, 308
MRA 172–3, 182–3, 336, 340, 343–6
MRI 54, 274, 299–302, 345
cardiac 300, 302
MS 296, 302–4
Multi-detector computed tomography. See MDCT
Multi-Ethnic Study of Atherosclerosis 186, 342
Multicenter Automatic Defi brillator Implantation Trial.
See MADIT
Multicenter UnSustained Tachycardia Trial. See MUSTT
Multifocal atrial tachycardia. See MAT
Murmurs 160, 294, 309
Muscle LIM protein. See MLP
Muscular dystrophy. See MD
MUSTT 273, 279–80
Mutations 238–41
disease-causing 238
sarcomere protein 238
MV
apparatus and LV function 305
gradient 304
morphology 302
repair 304–8
replacement 304–6, 311
surgery 308
MVA 303
Mycotic aneurysm. See MA
Myocardial infarction. See MI
Myocarditis 237–8, 241–2, 282
Myocardium 60–1, 72, 78–9, 81, 137, 145, 147, 149–51,
236–7, 239, 241–2
Myocytes 238, 241
Myotonic disease 241

N-acetylcysteine 173
Nadolol 227
Nafcillin 320–1
oxacillin-susceptible 320–1

Naproxen 85

National Cholesterol Education Program. See NCEP

National Cognitive and Skills examination 104–5

104

National Heart Lung and Blood Institute 222

National Heart, Lung, and Blood Institute. See NHLBI

Naxos disease 239

NCEP 48, 174, 176, 182, 187, 338

NCEP-ATP3 103

Necrosis, myocyte 242, 276

Nephropathy, overt diabetic 210

Nephrotic syndrome 192

Neurofi bromatosis 238, 241

Neurohormones 226

Neuromuscular disease 240, 284

Neuropathy 174

NHANES III 199, 200

NHLBI 166

Obesity Education Initiative 191

Niacin 219

NICM 272, 279

Nicotinic acid 190, 192–3

Nieman–Pick disease 241

Nifedipine 65

Nitrates 17–8, 34, 54, 67, 70, 78–9, 208–9, 230, 232

Nitrogen, blood urea 225

Nitroglycerin. See NTG

Nodosa, polyarteritis 344

Nondihydropyridine 212

Nonparoxysmal junction tachycardia 262–3

Nonsteroidal anti-infl ammatory drugs. See NSAIDs

Noonan syndrome 238, 241

Norepinephrine 226

NSAIDs 26, 33, 54, 78, 85

NSTEMI 118, 145, 147–9

NTG 28, 31, 33–4, 41, 48, 54, 66–7, 162

intraoperative 162

intravenous 54

sublingual 48, 84

Nutritional counseling 94

Obesity 188–9, 191–3, 214, 221, 234, 270, 283

Occlusion, arterial 168–9, 179–80, 182–3, 185–6

Off-pump CABG. See OPCAB

Olmesartan 227

OPCAB 137–8, 142, 145

Osler’s nodes 314

Outpatient parenteral antibiotic therapy 331

Oxacillin 320–1

Oximetry, pulse 33, 66

Oxygen, supplemental 33, 54, 66, 68, 70

Oxygenation 290

Oxygenator, membrane versus bubble 138